The use of E. faecium probiotic and autoprobiotic in patients with type 2 diabetes mellitus

Abstract

BACKGROUND: Bacteria in the gastrointestinal tract regulate eating behavior and metabolic processes. A number of probiotic strains have a positive effect on glucose and insulin metabolism. A series of studies have demonstrated the effectiveness of autoprobiotic therapy in the treatment of patients with gastrointestinal diseases. The efficacy and safety of an indigenous strain of Enterococcus faecium in overweight patients with type 2 diabetes has not been studied in the past.

AIM: To evaluate the effectiveness of products containing the probiotic strain Enterococcus faecium L3 or the indigenous strain Enterococcus faecium in patients with diabetes mellitus (DM) type 2.

MATERIALS AND METHODS: Patients with diabetes mellitus type 2 were randomized into two groups: group of probiotic therapy with an industrial strain of Enterococcus faecium L3 (11 patients); group of autoprobiotic therapy based on an indigenous strain of Enterococcus faecium (9 patients). Therapy was for 14 days. Before and 10-14 days after the end of therapy, anthropometric parameters were assessed; psychometric testing was carried out; biochemical parameters of blood serum were studied. The intestinal microbiota was studied by real-time polymerase chain reaction.

RESULTS: Probiotic therapy based on Enterococcus faecium L3 and autoprobiotic therapy based on indigenous Enterococcus faecium had no significant effect on glucose metabolism in patients with type 2 DM. In the Enterococcus faecium L3 group and the group of indigenous Enterococcus faecium there was a significant decrease in gastroenterological complaints on scales of the GSRS questionnaire. Patients in both groups showed a statistically significant decrease in the total bacterial mass, an increase in the quantitative content of Lactobacillus spp., a decrease in the population of Bifidobacterium spp. and Bacteroides thetaiotaomicron.

CONCLUSIONS: The probiotic strain Enterococcus faecium L3 and the indigenous Enterococcus faecium do not have a significant effect on the metabolism of glucose and insulin, while they contribute to a similar change in the component composition of the microbiota and a decrease in the severity of gastroenterological complaints.

Keywords

type 2 diabetes mellitus / obesity / insulin / probiotic / autoprobiotic / Enterococcus faecium L3 / indigenous Enterococcus faecium / GSRS questionnaire

References

[1] Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028–1044. DOI: 10.1016/j.cmet.2019.03.009

[2] Ling C., Rönn T. Epigenetics in human obesity and type 2 diabetes // Cell Metab. 2019. Vol. 29, No. 5. P. 1028–1044. DOI: 10.1016/j.cmet.2019.03.009

[3] Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2019;9(3):e017995. DOI: 10.1136/bmjopen-2017-017995

[4] Koutnikova H., Genser B., Monteiro-Sepulveda M. et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials // BMJ Open. 2019. Vol. 9, No. 3. P. e017995. DOI: 10.1136/bmjopen-2017-017995

[5] Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214. DOI: 10.1126/science.1241214

[6] Ridaura V.K., Faith J.J., Rey F.E. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice // Science. 2013. Vol. 341, No. 6150. P. 1241214. DOI: 10.1126/science.1241214

[7] Stanislawski MA, Dabelea D, Lange LA, et al. Gut microbiota phenotypes of obesity. NPJ Biofilms Microbiomes. 2019;5(1):18. DOI: 10.1038/s41522-019-0091-8

[8] Stanislawski M.A., Dabelea D., Lange L.A. et al. Gut microbiota phenotypes of obesity // NPJ Biofilms Microbiomes. 2019. Vol. 5, No. 1. P. 18. DOI: 10.1038/s41522-019-0091-8

[9] Ojo O, Feng QQ, Ojo OO, Wang XH. The role of dietary fibre in modulating gut microbiota dysbiosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Nutrients. 2020;12(11):3239. DOI: 10.3390/nu12113239

[10] Ojo O., Feng Q.Q., Ojo O.O., Wang X.H. The role of dietary fibre in modulating gut microbiota dysbiosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials // Nutrients. 2020. Vol. 12, No. 11. P. 3239. DOI: 10.3390/nu12113239

[11] Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. DOI: 10.1038/nrgastro.2014.66

[12] Hill C., Guarner F., Reid G. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic // Nat. Rev. Gastroenterol. Hepatol. 2014. Vol. 11, No. 8. P. 506–514. DOI: 10.1038/nrgastro.2014.66

[13] Wang J, Tang H, Zhang C, et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 2015;9(1):1–15. DOI: 10.1038/ismej.2014.99

[14] Wang J., Tang H., Zhang C. et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice // ISME J. 2015. Vol. 9, No. 1. P. 1–15. DOI: 10.1038/ismej.2014.99

[15] Gomes AC, Bueno AA, de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J. 2014;13:60. DOI: 10.1186/1475-2891-13-60

[16] Gomes A.C., Bueno A.A., de Souza R.G., Mota J.F. Gut microbiota, probiotics and diabetes // Nutr. J. 2014. Vol. 13. P. 60. DOI: 10.1186/1475-2891-13-60

[17] Ruan Y, Sun J, He J, et al. Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials. PLoS One. 2015;10(7):e0132121. DOI: 10.1371/journal.pone.0132121

[18] Ruan Y., Sun J., He J. et al. Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials // PLoS One. 2015. Vol. 10, No. 7. P. e0132121. DOI: 10.1371/journal.pone.0132121

[19] Sun J, Buys NJ. Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials. Br J Nutr. 2016;115(7):1167–1177. DOI: 10.1017/S0007114516000076

[20] Sun J., Buys N.J. Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials // Br. J. Nutr. 2016. Vol. 115, No. 7. P. 1167–1177. DOI: 10.1017/S0007114516000076

[21] Giampieri F, Tulipani S, Alvarez-Suarez JM, et al. The strawberry: composition, nutritional quality, and impact on human health. Nutrition. 2012;28(1):9–19. DOI: 10.1016/j.nut.2011.08.009

[22] Giampieri F., Tulipani S., Alvarez-Suarez J.M. et al. The strawberry: composition, nutritional quality, and impact on human health // Nutrition. 2012. Vol. 28, No. 1. P. 9–19. DOI: 10.1016/j.nut.2011.08.009

[23] Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, et al. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012;28(5):539–543. DOI: 10.1016/j.nut.2011.08.013

[24] Ejtahed H.S., Mohtadi-Nia J., Homayouni-Rad A. et al. Probiotic yogurt improves antioxidant status in type 2 diabetic patients // Nutrition. 2012. Vol. 28, No. 5. P. 539–543. DOI: 10.1016/j.nut.2011.08.013

[25] Probiotics and prebiotics [Internet]. World Gastroenterology Organisation Global Guidelines. 2017. Available from: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english. Accessed: Feb 23, 2022.

[26] Probiotics and prebiotics [Электронный ресурс] // World Gastroenterology Organisation Global Guidelines. 2017. Режим доступа: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-russian. Дата обращения: 23.02.2022.

[27] Gonchar NV, Alyokhina LA, Suvorov AN. Probiotic strains of enterococci as a means of therapy and prevention of intestinal diseases in children (literature review). Experimental and clinical gastroenterology. 2013;(1):74–78. (In Russ.)

[28] Гончар Н.В., Алехина Л.А., Суворов А.Н. Пробиотические штаммы энтерококков как средства терапии и профилактики заболеваний кишечника у детей (обзор литературы) // Экспериментальная и клиническая гастроэнтерология. 2013. № 1. С. 74–78.

[29] Emaneini M, Hosseinkhani F, Jabalameli F, et al. Prevalence of vancomycin-resistant enterococcus in Iran: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2016;35(9):1387–1392. DOI: 10.1007/s10096-016-2702-0

[30] Emaneini M., Hosseinkhani F., Jabalameli F. et al. Prevalence of vancomycin-resistant Enterococcus in Iran: a systematic review and meta-analysis // Eur. J. Clin. Microbiol. Infect. Dis. 2016. Vol. 35, No. 9. P. 1387–1392. DOI: 10.1007/s10096-016-2702-0

[31] Ermolenko EI, Voejkova AV, Suvorov AN. Influence of metabolites secreted by enterococcus cultures on the growth of mycoplasmas. Excerpt from VI Russian Congress of Infectious Disease Physicians, Russian Federation; Oct 29–31, 2003. Saint Petersburg; 2003. P. 72–73. (In Russ.)

[32] Ермоленко Е.И., Воейкова А.В., Суворов А.Н. Влияние метаболитов, выделяемых культурами энтерококка на рост микоплазм // Сборник тезисов VI Российского Съезда врачей-инфекционистов. Санкт-Петербург, 29–31 октября 2003 г. СПб., 2003. С. 72–73.

[33] Averina OV, Ermolenko EI, Ratushny AYu, et al. Effect of probiotics on cytokine production in in vitro and in vivo systems. Medical immunology. 2015;17(5):443–454. (In Russ.). DOI: 10.15789/1563-0625-2015-5-443-454

[34] Аверина О.В., Ермоленко Е.И., Ратушный А.Ю. и др. Влияние пробиотиков на продукцию цитокинов в системах in vitro и in vivo // Медицинская иммунология. 2015. Т. 17, № 5. С. 443–454. DOI: 10.15789/1563-0625-2015-5-443-454

[35] Ermolenko EI. Lactic acid bacteria. Lambert academic Publishing, Deutschland Lambert; 2011. (In Russ.)

[36] Ермоленко Е.И. Молочнокислые бактерии. Lambert academic Publishing, Deutchland Lambert; 2011.

[37] Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol. 2008;14(2):313–317. DOI: 10.3748/wjg.14.313

[38] Wu W.C., Zhao W., Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats // World J. Gastroenterol. 2008. Vol. 14, No. 2. P. 313–317. DOI: 10.3748/wjg.14.313

[39] Il’in VK, Suvorov AN, Kiriukhina NV, et al. Autochthonous probiotics in prevention of infectious and inflammatory diseases of a human in the altered habitats. Vestn Ross Akad Med Nauk. 2013;68(2):56–62. (In Russ.). DOI: 10.15690/vramn.v68i2.550

[40] Ильин В.К., Суворов А.Н., Кирюхина Н.В. и др. Аутопробиотики как средство профилактики инфекционно-воспалительных заболеваний у человека в искусственной среде обитания // Вестник Российской академии медицинских наук. 2013. Т. 68, № 2. С. 56–62. DOI: 10.15690/vramn.v68i2.550

[41] Ermolenko EI, Yerofeev NP, Zakharova LB, et al. Influence of endogenous enterococci on microbiota. Features of the motor function of the colon in experimental dysbiosis. Zdorov’e – osnova chelovecheskogo potenciala: problemy i puti ikh resheniya =Health – the basis of human potential: problems and ways of their solution. 2016;11(2):769–781. (In Russ.)

[42] Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б. и др. Влияние индигенных энтерококков на микробиоту. Особенности двигательной функции толстой кишки при экспериментальном дисбиозе // Здоровье — основа человеческого потенциала: проблемы и пути их решения. 2016. Т. 11, № 2. С. 769–781.

[43] Donets VN. Possibilities of probiotic therapy of community-acquired pneumonia (clinical and experimental study) [dissertation]. Saint Petersburg; 2015. (In Russ.)

[44] Донец В.Н. Возможности пробиотической терапии внебольничных пневмоний (клинико-экспериментальное исследование): автореф. дисс. ... канд. мед. наук. СПб., 2015.

[45] Zeng Q, Li D, He Y, et al. Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities. Sci Rep. 2019;9(1):13424. DOI: 10.1038/s41598-019-49462-w

[46] Zeng Q., Li D., He Y. et al. Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities // Sci. Rep. 2019. Vol. 9, No. 1. P. 13424. DOI: 10.1038/s41598-019-49462-w

[47] Wang L, Alammar N, Singh R, et al. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J Acad Nutr Diet. 2020;120(4):565–586. DOI: 10.1016/j.jand.2019.05.015

[48] Wang L., Alammar N., Singh R. et al. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies // J. Acad. Nutr. Diet. 2020. Vol. 120, No. 4. P. 565–586. DOI: 10.1016/j.jand.2019.05.015

[49] Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23(7):859–868. DOI: 10.1038/nm.4358

[50] Liu R., Hong J., Xu X. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention // Nat. Med. 2017. Vol. 23, No. 7. P. 859–868. DOI: 10.1038/nm.4358

[51] Bhattarai Y, Williams BB, Battaglioli EJ, et al. Gut microbiota-produced tryptamine activates an epithelial g-protein-coupled receptor to increase colonic secretion. Cell Host Microbe. 2018;23(6):775–785.e5. DOI: 10.1016/j.chom.2018.05.004

[52] Bhattarai Y., Williams B.B., Battaglioli E.J. et al. Gut microbiota-produced tryptamine activates an epithelial g-protein-coupled receptor to increase colonic secretion // Cell Host Microbe. 2018. Vol. 23, No. 6. P. 775–785.e5. DOI: 10.1016/j.chom.2018.05.004

RIGHTS & PERMISSIONS

Bakulina N.V., Tikhonov S.V., Ermolenko E.I., Kotyleva M.P., Lavrenova N.S., Topalova Y.G., Simanenkov V.I., Suvorov A.N.